3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
110
Carcinoma, Non-Small-Cell Lung
63
Lung Neoplasms
27
Hodgkin Disease
14
Lymphoma
10
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
8
Neoplasms
8
Recurrence
7
Prostatic Neoplasms
7
Small Cell Lung Carcinoma
5
Sarcoma
5
Rhabdomyosarcoma
5
Lymphoma, Large B-Cell, Diffuse
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Breast Neoplasms, Male
4
Brain Neoplasms
4
Adenocarcinoma of Lung
4
Ovarian Neoplasms
3
NSCLC
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Esophageal Squamous Cell Carcinoma
3
Interventions
Dexamethasone
16
Calcium Dobesilate
9
Melphalan
6
Lenalidomide
6
Cyclophosphamide
5
Bortezomib
5
pomalidomide
3
venetoclax
2
daratumumab
2
Thalidomide
2
Doxycycline
2
Biopsy
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
belantamab mafodotin
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Interleukin-2
1
In Situ Hybridization, Fluorescence
1
In Situ Hybridization
1
Hyaluronoglucosaminidase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Amyloidosis
×
Vinorelbine
×
Clear all
NCT02791373
2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2
Completed
136 enrolled